Nuvation Bio enrolls first patient in TRUST-IV Phase 3 study of IBTROZI

Nuvation Bio (NUVB) announced it has enrolled the first patient in TRUST-IV, a Phase 3 study evaluating the efficacy and safety of IBTROZI, a next-generation ROS1 inhibitor, versus placebo for the adjuvant treatment of patients with resected ROS1-positive early-stage non-small cell lung cancer, NSCLC. Following alignment with the U.S. Food and Drug Administration on study design, TRUST-IV will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China with ROS1+ stage IB, II or IIIA NSCLC who have received surgery for their disease. The primary endpoint is disease-free survival as determined by investigator. Primary completion date is estimated to be in 2033.